Condition: Metastatic HER2-positive Breast Cancer · Sponsor: Jazz Pharmaceuticals
The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, previous T-DXd treatment.
This description comes directly from the study's public registry record.
Clinical Trial Disclosure & Transparency · 215-832-3750 · ClinicalTrialDisclosure@JazzPharma.com
Always discuss trial participation with your own doctor first.
| Mayo Clinic Scottsdale - PPDS | Phoenix, Arizona, United States | Recruiting |
| Arizona Oncology Tucson - Wilmot | Tucson, Arizona, United States | Withdrawn |
| University of Arizona Cancer Center | Tucson, Arizona, United States | Recruiting |
| The Oncology Institute Of Hope And Innovation | Cerritos, California, United States | Recruiting |
| Los Angeles Hematology Oncology Medical Group Glendale | Glendale, California, United States | Recruiting |
| USC-Norris Comprehensive Cancer Center - Investigational Drug Service IDS | Los Angeles, California, United States | Recruiting |
| UCSF at Mission Bay MB | San Francisco, California, United States | Recruiting |
| University of Colorado-Cancer Center-PPDS | Aurora, Colorado, United States | Recruiting |
| Rocky Mountain Cancer Centers | Denver, Colorado, United States | Recruiting |
| Medstar Georgetown University Hospital | Washington D.C., District of Columbia, United States | Recruiting |
| Washington Cancer Center | Washington D.C., District of Columbia, United States | Recruiting |
| Florida Cancer Specialists Research South | Fort Myers, Florida, United States | Recruiting |
+ 154 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06435429